Stoke Therapeutics, Inc. Expected to Post FY2024 Earnings of ($2.51) Per Share (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at HC Wainwright raised their FY2024 earnings per share estimates for Stoke Therapeutics in a research note issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($2.51) for the year, up from their previous estimate of ($2.62). HC Wainwright currently has a "Buy" rating and a $35.00 target price on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.28) per share. HC Wainwright also issued estimates for Stoke Therapeutics' FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($2.57) EPS and FY2027 earnings at ($0.90) EPS.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Monday, March 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.02. The business had revenue of $2.80 million during the quarter, compared to the consensus estimate of $3.70 million.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. upped their price objective on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a "neutral" rating in a research report on Tuesday, March 26th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Monday. Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. TD Cowen upgraded Stoke Therapeutics from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 26th. Finally, Canaccord Genuity Group decreased their price target on shares of Stoke Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $20.57.

Stoke Therapeutics Price Performance

NASDAQ:STOK traded down $0.53 during trading hours on Friday, hitting $11.48. 753,363 shares of the company traded hands, compared to its average volume of 936,575. The firm has a 50-day moving average of $10.39 and a 200 day moving average of $6.75. Stoke Therapeutics has a twelve month low of $3.35 and a twelve month high of $16.40.

Institutional Trading of Stoke Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of STOK. SG Americas Securities LLC bought a new position in Stoke Therapeutics in the 3rd quarter valued at $53,000. Bank of New York Mellon Corp boosted its holdings in Stoke Therapeutics by 2.8% in the third quarter. Bank of New York Mellon Corp now owns 107,254 shares of the company's stock valued at $423,000 after acquiring an additional 2,926 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Stoke Therapeutics by 9.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company's stock worth $576,000 after purchasing an additional 12,478 shares during the period. Dorsey & Whitney Trust CO LLC bought a new stake in Stoke Therapeutics during the 3rd quarter worth about $43,000. Finally, Trexquant Investment LP lifted its position in Stoke Therapeutics by 166.9% during the 3rd quarter. Trexquant Investment LP now owns 127,581 shares of the company's stock valued at $503,000 after purchasing an additional 79,785 shares during the period.

Insider Activity

In other news, CFO Stephen J. Tulipano sold 4,116 shares of the firm's stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the sale, the chief financial officer now owns 20,746 shares of the company's stock, valued at $126,550.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO Edward M. Md Kaye sold 11,150 shares of the company's stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the transaction, the chief executive officer now owns 69,350 shares in the company, valued at approximately $423,035. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Stephen J. Tulipano sold 4,116 shares of the firm's stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the sale, the chief financial officer now owns 20,746 shares of the company's stock, valued at approximately $126,550.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,622,741 shares of company stock worth $41,935,115. Corporate insiders own 11.30% of the company's stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.